Should You Buy Bruker Corp (BRKR) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
44.480
1 Day change
-4.45%
52 Week Range
59.400
Analysis Updated At
2026/01/28
Buy BRKR now for a long-term position. The stock is trading near key support (~46.8) with a washed-out short-term setup (RSI near 31) while Wall Street price targets have been repeatedly raised into 2026 on expectations for a recovery and better margin trajectory. Even though recent quarterly fundamentals were weak, current pricing looks more like a “buy-the-dip” long-term entry than a chase, and options positioning is modestly bullish (put/call ratios below 1).
Technical Analysis
Price/levels: BRKR at 47.22 is just above S1 support (46.8) and not far from S2 (45.035). The pivot/overhead level is 49.658 (a likely near-term ceiling); resistance levels are 52.515 and 54.28.
Trend/momentum: MACD histogram is negative (-0.625) and expanding lower, indicating bearish momentum still in control. RSI(6) at ~30.7 is near oversold territory, suggesting downside may be getting exhausted and the risk/reward is improving for a long-term entry near support.
Moving averages: converging moving averages typically indicate consolidation after a move; combined with the MACD, this leans “weak trend / basing attempt,” not a confirmed uptrend yet.
Short-term probability read: pattern-based stats imply mild downside bias over the next week (-2.51%) with a modest rebound potential over the next month (+1.22%). Net: technically weak short-term, but positioned near support where long-term buyers often step in.
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: Both open-interest and volume put/call ratios are below 1 (0.79 OI, 0.62 volume), which is generally bullish/constructive (more call positioning than puts).
Activity: Today’s options volume is elevated vs typical (today vs 30-day avg volume ~34.71), suggesting increased attention/positioning.
Volatility: 30D IV ~55.47 vs historical vol ~39.74 implies options are pricing above recent realized movement; IV percentile ~56.8 is mid-range (not extreme). Net: options market leans moderately bullish, but expects meaningful movement.
Technical Summary
Sell
8
Buy
6
Positive Catalysts
1) Analyst-driven 2026 recovery narrative: multiple firms raised targets and expect improving end-markets for Life Science Tools/Diagnostics.
2) Visibility/backlog: Wolfe highlighted semiconductor orders shifting into 1H26 with ~7 months of backlog, supporting forward revenue visibility.
3) Event catalyst: Next earnings (QDEC 2025) on 2026-02-12 pre-market (EPS est. 0.65) can reset sentiment quickly if guidance confirms recovery.
4) Positioning: Options put/call ratios (<1) suggest the derivatives market is not defensively positioned.
Neutral/Negative Catalysts
1) Weak latest reported quarter (2025/Q3): slight revenue decline YoY and a swing to a net loss with margin deterioration—this is a real fundamental headwind until the recovery shows up in reported numbers.
2) Technical momentum is still bearish: MACD histogram is negative and worsening, so the stock can still probe lower supports (46.8 / 45.0) before stabilizing.
3) No near-term news tailwinds: no major positive news flow in the last week to spark immediate rerating.
4) Upcoming earnings risk: the next report (2026-02-12) is a binary sentiment event if guidance or margins disappoint.
Financial Performance
Latest quarter provided: 2025/Q3.
- Revenue: 860.5M, down -0.45% YoY (flat-to-down growth).
- Net income: -62.4M, down -252.57% YoY (loss; sharp deterioration).
- EPS: -0.41, down -251.85% YoY.
- Gross margin: 46.44%, down -4.42% YoY.
Read-through: fundamentals in Q3 were clearly soft (profitability and margins notably worse), which is why the investment case leans heavily on a 2026 recovery/normalization rather than current-quarter strength.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Strongly improving sentiment via a cluster of upgrades/price-target raises from Dec 2025 through Jan 2026.
- Bullish actions: Guggenheim (Buy, PT raised to 58 from 53; earlier raised to 53), JPMorgan (Overweight, PT 55), BofA (Buy, PT 60), Barclays (Overweight, PT 55), Wells Fargo (Overweight, PT 55), Wolfe (upgrade to Outperform, PT 60).
- More cautious: Citi remains Neutral (though PT raised to 53), TD Cowen keeps Hold (PT raised to 53).
Wall Street pros view: 2026 recovery setup, margin expansion potential, and improved visibility/backlog drive upside targets well above the current ~47 level.
Wall Street cons view: near-term results bar is higher after sector rallies and 2026 guidance is key; some firms still hold/neutral pending proof in reported numbers.
Other flows: Hedge funds and insiders are reported Neutral; no recent congress trading data available.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 52.18 USD with a low forecast of 40 USD and a high forecast of 60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 46.550
Low
40
Averages
52.18
High
60
Current: 46.550
Low
40
Averages
52.18
High
60
Guggenheim
Buy
maintain
$53 -> $58
AI Analysis
2026-01-26
New
Reason
Guggenheim
Price Target
$53 -> $58
AI Analysis
2026-01-26
New
maintain
Buy
Reason
Guggenheim raised the firm's price target on Bruker to $58 from $53 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Citi
Neutral
maintain
$40 -> $53
2026-01-16
Reason
Citi
Price Target
$40 -> $53
2026-01-16
maintain
Neutral
Reason
Citi raised the firm's price target on Bruker to $53 from $40 and keeps a Neutral rating on the shares. The firm adjusted targets in the life science tools and diagnostics group after meeting with companies. Commentary around pharma was positive, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BRKR
